TLN-372 in Advanced KRAS Mutant Solid Tumors
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Treeline Biosciences, Inc.
- Study ID
- NCT07204340
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- KRAS Mutant Solid Tumors
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- TLN-372 — DRUGSpecified dose on specified days
- TLN-372 in combination with cetuximab — DRUGSpecified dose on specified days
- TLN-372 in combination with pembrolizumab — DRUGSpecified dose on specified days
Study Details
The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors
Key Dates
- Start date
- Sep 29, 2025
- Status verified
- Apr 2026
- Primary completion
- Dec 3, 2031
- Completion
- Apr 1, 2032
Study Design
- Enrollment
- 240 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Single Agent
- Experimental: Combination Treatment
Primary Outcome Measure
Number of patients experiencing adverse events (AEs) that meet protocol-defined dose-limiting toxicity (DLT) criteria following administration of TLN-372 [ Time Frame: Up to 2 years ]
Central Contacts
- Treeline Clinical Operations857-228-0050
Locations (6)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | Rebecca Arend |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215-5450 | |
| START Midwest | Grand Rapids | Michigan | 49546 | |
| Washington University Medical Campus | St Louis | Missouri | 63108 | |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10021-3402 | Jamie Walters 917-843-7966 |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 |